I-Mab (the “Company”) (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient has been dosed in a phase 2 clinical trial ( NCT04600817 ) of TJ107 (efineptakin alpha), a novel long-acting reco
February 4, 2021
· 6 min read